# NUCALA® Special Drug Use Investigation (EGPA, Long-term)

> **NCT03557060** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 4115 (actual)

## Conditions studied

- Churg-Strauss Syndrome
- Eosinophilic Granulomatosis With Polyangiitis

## Interventions

- **DRUG:** Nucala

## Key facts

- **NCT ID:** NCT03557060
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-25
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 4115 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03557060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03557060, "NUCALA® Special Drug Use Investigation (EGPA, Long-term)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03557060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*